{'fraction_non_alphanumeric': 0.04984423676012461, 'fraction_numerical': 0.04672897196261682, 'mean_word_length': 5.361386138613861, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Retrospective analysis of 133 patients with cutaneous lymphomas from a single Japanese medical center between 1995 and 2008

In 2008, a revised World Health Organization (WHO) system of hematological neoplasm classification was promulgated. Between January 1995 and December 2008, 133 new patients with cutaneous lymphomas were seen at the dermatology clinic of Okayama University Hospital. All patients were re‐classified according to the revised WHO system. The incidence rates were analyzed and the survival was estimated. Of 133 patients, 106 (79.7%) had primary cutaneous lymphomas (PCLs) and 27 (20.3%) were skin invasion from extracutaneous origin of systemic lymphoma. Compared with several reports from western countries, “mature T‐cell and NK‐cell neoplasms” was frequent in this study (87% vs. 77 or 72%) because of the occurrence of adult T‐cell leukemia/lymphoma (ATLL) and “extranodal NK/T cell lymphoma, nasal type”, with less frequent occurrence of “mature B‐cell neoplasms” (13% vs. 23 or 28%). Estimated survival of patients with mycosis fungoides was favorable (5‐year survival rate 90.6%), but that of the patients with primary cutaneous anaplastic large cell lymphoma (C‐ALCL) was extremely less favorable than previously reported (5‐year survival rate of 47.4%).